EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Do people with HIV really have the choice between oral and injectable ART ? Evidence from a multicentric survey in the Swiss HIV cohort study

Yonas Martin iD, Bernard Surial iD, Martin Müller, Lukas Baumann iD, David Jackson-Perry, David Haerry, Marie Ballif iD, Charles Béguelin, Miriam Bürgi, Aline Munting, Matthias Cavassini iD, Dominique Braun und 4 weitere

HIV Medicine · 2026

DOI: 10.1111/hiv.70239 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift HIV Medicine, 2026. Verfasst von Yonas Martin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Patient Preference. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss HIV Cohort Research Foundation, Wellcome Trust, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Injectable long‐acting antiretroviral therapy (iLA‐ART) offers a valuable alternative to oral ART (oART). While the efficacy of these treatment strategies is similar, adequate information on their specific characteristics is essential to enable people with HIV (PWH) to decide which option best suits their values and preferences.

Methods

We conducted a multicentric survey of PWH on oART in the Swiss HIV Cohort Study (SHCS). Using a questionnaire co‐developed with expert patients, we assessed participants' (1) values and preferences on characteristics of modern oART and treatment satisfaction, (2) knowledge about iLA‐ART with cabotegravir/rilpivirine, (3) reasons influencing their interest to switch or not to iLA‐ART and (4) perceived burden of treatment (BOT) taking oART. Outcomes were rated on an 11‐point (0–10) Likert scale. We explored outcomes' determinants using multivariate analyses.

Results

A total of 200 PWH on oART participated (response rate 87%), with a median age of 52 years (Interquartile Range 45–59), 58 (29%) were women, and 90 (45%) were men who have sex with men. Treatment satisfaction was very high (mean 9.3, Standard Deviation [SD] 1.3) and perceived BOT on oART was low (mean 2.5, SD 2.0). The two most valued oART characteristics were effectiveness (mean 9.9, SD 0.3) and absence of side effects (mean 9.5, SD 1.7). Overall, 76 (39%) participants had never heard about iLA‐ART, with large differences between the 3 participating centres (60% vs. 3% vs. 50%). In multivariable analysis, women (Odds Ratio 0.35, 95% confidence interval [CI] 0.14–0.85) and PWH ≥60 years (0.27, 0.08–0.94) were less aware about iLA‐ART. Reasons influencing PWH's potential interest to switch to iLA‐ART varied individually, while the main reason for preferring to stay on oART was the bimonthly dosing interval of iLA‐ART.

Conclusion

In Switzerland, over one‐third of PWH were unaware of iLA‐ART despite its reimbursed availability. The provider of care appears to be the main driver of these findings, while women and older individuals showed the lowest awareness. As ART characteristics are valued individually, providing systematic information on available treatment options and engaging PWH in shared decision‐making could help address identified disparities and empower them to choose the treatment that best aligns with their preferences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsPatient PreferenceHumansMaleFemaleMiddle AgedSwitzerlandSurveys and QuestionnairesAdministration, OralCohort StudiesPatient SatisfactionAdultInjectionsChoice BehaviorPyridonesDiketopiperazines

Stichwörter der Autor:innen

HIVantiretroviral agentsinjectable ART; shared decision makinglong‐acting ARTpatient preference

Substanzen

Anti-HIV AgentscabotegravirPyridonesDiketopiperazines

Autor:innen und Institutionen

  • Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Emergency Medicine, Inselspital, Bern University Hospital, Bern University, Bern, Switzerland.
  • Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Positive Council Switzerland, Zurich, Switzerland.
  • Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Department of Internal Medicine, Spitalzentrum Biel, Biel/Bienne, Switzerland.

ORCID-Profile: Yonas Martin, Bernard Surial, Lukas Baumann, Marie Ballif, Matthias Cavassini, Andri Rauch

Förderung

  • Swiss HIV Cohort Research Foundation
  • Wellcome Trust
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Martin, Y., Surial, B., Müller, M., Baumann, L., Jackson-Perry, D., Haerry, D., Ballif, M., Béguelin, C., Bürgi, M., Munting, A., Cavassini, M., Braun, D., Rauch, A., Auer, R., Wandeler, G., & Swiss HIV Cohort Study (2026). Do people with HIV really have the choice between oral and injectable ART ? Evidence from a multicentric survey in the Swiss HIV cohort study. HIV Medicine. https://doi.org/10.1111/hiv.70239

Vancouver

Martin Y, Surial B, Müller M, Baumann L, Jackson-Perry D, Haerry D, et al. Do people with HIV really have the choice between oral and injectable ART ? Evidence from a multicentric survey in the Swiss HIV cohort study. HIV Medicine. 2026. doi:10.1111/hiv.70239

BibTeX
@article{Martin2026,
  author = {Martin, Yonas and Surial, Bernard and Müller, Martin and Baumann, Lukas and Jackson-Perry, David and Haerry, David and Ballif, Marie and Béguelin, Charles and Bürgi, Miriam and Munting, Aline and Cavassini, Matthias and Braun, Dominique and Rauch, Andri and Auer, Reto and Wandeler, Gilles and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
  title = {Do people with HIV really have the choice between oral and injectable ART ? Evidence from a multicentric survey in the Swiss HIV cohort study},
  journal = {HIV Medicine},
  year = {2026},
  doi = {10.1111/hiv.70239}
}
Kostenlos starten →